Abstract
Introduction

The major histocompatibility complex (MHC) class I gene HLA-B27 has a striking association with a group of human inflammatory disorders that affect the bowel, the joints and the axial skeleton, known as spondyloarthritis (SpA). Extensive endoscopic and histological studies have demonstrated that 5-10% of patients with ankylosing spondylitis (AS, the prototype of these disorders) have inflammatory bowel disease (IBD). Moreover, about twothirds of SpA patients have microscopic signs of gut inflammation without clinical symptoms, but about 6-13% of them develop IBD
during the disease course [1, 2] .
In an attempt to create an animal model of B27-associated disease, inbred rats expressing both HLA-B27 and its associated light chain human ␤2-microglobulin (HLA-B27/h␤2m) were developed [3] . HLA-B27 transgenic rats (B27TR) on LEW background as well as commercially available B27TR on Fisher F344 background [4, 5] , including colitis and arthritis [3, 6] . A progressive chronic gastrointestinal inflammation spontaneously develops in these rats, showing a predominant Th1 inflammatory cytokine pattern [7] . B27TR are well recognized as an animal model of IBD [7] . The susceptibility to disease and the level of expression of the HLA-B27 allele (but not h␤2m) are strictly associated, and a threshold of HLA-B27 transgene copies exists, above which disease predictably arises [6, 8] .
In B27TR, both CD4+ T cells and antigen-presenting cells (APCs) expressing high levels of HLA-B27 seem to be of critical importance in the pathogenesis of the disease [6, 9] . APCs have relatively poor efficacy in stimulating T cells [10] , and this could result in loss of tolerance toward self-antigens. Alternatively (or additionally), impaired T-cell stimulation could result in altered control of gut bacteria, thereby sustaining stimulation of immune defence by macrophages [9] . Indeed, IBD and arthritis symptoms can be prevented in 'germ-free' conditions, while bacterial flora reconstitution fosters disease development [11] .
Several mediators of inflammation were detected in B27TR colonic mucosa [9, 11, 12] . An increase of IFN␥ and IL-2 was found in the early phase, suggesting a predominantly Th1-mediated response, while in advanced disease IL-1 and TNF␣ are expressed [9, 11, 12] . TNF␣ stimulates the development of the socalled 'semi-mature' dendritic cells (DCs), which are critical for tolerance induction [13] . Administration of recombinant murine IL-10, which down-regulates TNF␣, to B27TR with established disease, despite the inhibition of the production of this cytokine in the gut mucosa, had no effect on the disease course arguing a critical role of TNF␣ in initiating the process [14] .
Anti [16] .
TNF␣ plays an essential role in regulating intestinal epithelial cell (IEC) apoptosis and/or survival during chronic inflammation [17, 18] . Fas/CD95/APO-1 is a death receptor of the TNF␣ receptor family, and engagement of its ligand (Fas-L) initiates a series of intracellular events leading to programmed cell death [17, [19] [20] [21] . Activated T cells, which produce TNF␣, can trigger the expression of Fas-L on non-lymphoid tissue, such as IEC, and this in turn can induce apoptosis in the T cells [17, [19] [20] [21] . This model is an example of 'inducible immune privilege' proposed to contribute to limiting the extent of infiltration by activated T cells into certain peripheral tissues [17] . TNF-R1, which is constitutively expressed by the IEC, mediates this mechanism. 
Materials and methods
Experimental design
Male HLA-B27/h␤2m transgenic rats (B27TR, n = 24) and male non-transgenic control rats (Fisher F344, n = 16) [22, 23] . In brief, the severity of the colonic lesions was 
Immunohistochemistry
The sections were de-waxed and heated in 10 
Evaluation of Fas/Fas-L-positive and apoptotic cells
Quantitative analysis on tissue sections (400ϫ magnification) was performed, considering as positive, for Fas/Fas-L, any epithelial and lamina propria cells exhibiting identifiable reactivity distinct from background. Morphologically preserved TUNEL-positive cells were referred to as apoptotic cells. For each animal, 10 random fields, with fully longitudinally sectioned crypts, from 2 sections of 4 different slides of the colon were examined, for a total of 80 fields and at least 1000 cells/section (immunoreactive and non-immunoreactive cells) counted. The apoptotic index (AI) was defined as the ratio of TUNEL-positive to total nuclei counted multiplied by 100.
Semiquantitative reverse-transcription polymerase chain reaction (RT-PCR) analysis
Results
Clinical evaluation
There were no significant differences in body weight gain between anti-TNF␣-treated and IgG2a,k-treated B27TR during the experimental period. At (Fig. 1A) .
weeks of age, both IgG2a,k-treated and untreated B27TR developed clinical signs of bowel inflammation (diarrhoea). In contrast, B27TR early-treated with anti-TNF␣ mAb manifested no signs of inflammation and the stool character remained normal for the duration of the experiment
In the late-treated group, clinical signs of inflammation improved after the first week of anti-TNF␣ mAb treatment, and stool score decreased and then normalized (Fig. 1B and C) . (Fig. 2B and C) . At 27 weeks of age, IgG2a,k-treated rats showed more severe damage than at 18 weeks (Fig. 2E) . (Fig. 2D) . (Fig. 2F) .
Histological analysis
The late treatment with anti-TNF␣ antibody did not induce a significant remission of the pathological signs of inflammation, despite clear clinical improvement
The histological score of colonic inflammation is reported in Fig. 2G .
Expression of TNF␣ receptors Immunohistochemistry
Colonic IEC of F344 rats showed a strong immunopositivity for TNF-R1 (Fig. 3A) . Specimens of IgG2a,k-treated B27TR were weakly stained or negative for TNF-R1 (Fig. 3B) . IEC of B27TR early-treated with anti-TNF␣ mAb showed a strong immunopositivity for TNF-R1, as F344 specimens (Fig. 3C) .
At 27 weeks of age, the colon of IgG2a,k-treated B27TR displayed negative immunostaining for TNF-R1 (Fig. 3D) . In the IEC, the late treatment increased the expression of TNF-R1 to levels similar to controls (Fig. 3E) .
TNF-R2 positivity was absent from the colon of F344 rats (Fig.  4A) , whereas a strong positivity was observed in the IgG2a,ktreated B27TR, both at 18 and 27 weeks of age (Fig. 4B and C) . In particular, some cells of the inflammatory infiltrate were strongly positive (Fig. 4B) . In the specimens from anti-TNF␣-treated B27TR, no staining for TNF-R2 was observed, both in early-and late-treated rats (Fig. 4D) . Fig. 4E and F) . (Fig. 5A and D (Fig. 6 and Table 4 ). Table 5 ). [24] . [22, [23] [24] [25] [26] [27] , which forms a physiological barrier against antigens and potential pathogenic microorganism in the gut lumen [28, 29] . [31, 32] . Many animal models of experimental colitis support the concept that IBD are caused by an aggressive immune response to commensal non-pathogenic bacteria in a genetically susceptible host [27] . In this context, the role of TNF␣ and its receptors is somewhat controversial and polymodal, depending on the tissue type and cell target [17, [33] [34] [35] [36] .
Semiquantitative RT-PCR
Fas and Fas-L expression
TUNEL assay
Apoptotic cells were rare and limited to the surface epithelium in F344 rats. B27TR showed a significantly increased AI within the
Serum cytokine levels
IL-1 levels were higher in IgG2a,k-treated B27TR, at 18 and 27 weeks of age, compared to F344 rats. The early anti-TNF␣ treatment inhibited the increase of IL-1, while the late treatment was not able to reduce the serum levels of IL-1 (Table 5). IL-2 was significantly higher in B27TR compared to F344, and anti-TNF␣ treatment did not affect the cytokine levels (
Discussion
Our data clearly show that TNF␣ blockade, used before the development of any clinical IBD manifestations, markedly inhibits the onset of colon inflammation in disease-prone HLA-B27 transgenic rats (B27TR). In contrast, when the disease symptoms are established, the treatment is significantly less efficacious, improving only clinical signs but not significantly reducing the pathological features. The intestinal epithelium, which is part of the innate immune system, plays an active role in the maintenance of mucosal homeostasis [24]. Aberrant secretion of proinflammatory chemokines and cytokines, such as TNF␣, IL-1 and IL-6, by epithelial cells is an integral part of the dysregulated immune response that initiates or perpetuates intestinal inflammation
B27TR is an experimental model of colitis, which has been used for several years to evaluate the activity and mechanisms of actions of anti-inflammatory molecules
. Our study was focused on the effect of TNF␣ blockade on intestinal inflammation, both as preventive and rescue treatment. When used early, TNF␣ blockade significantly prevented the onset of clinical manifestations and pathological manifestations while, in the advanced phase of IBD, it was able to ameliorate but not resolve the symptoms. The histopathological damage observed at 18 weeks was effectively prevented by TNF␣ blockade. Several experimental models suggest that the aetiology of IBD is not only related to immune abnormalities but also to a defect of the epithelial cell layer
The protective effect shown by the integrity of the epithelial cell layer in the specimens of the early-treated rats is an important finding, corroborating the positive effect of anti-TNF␣ on the course of mucosal inflammation. The striking efficacy of the early treatment might be also due to a relatively low or absent inflammation in the animals at the beginning of the experiment, considering the absence of clinical signs. After 18 weeks, the observed pathological modifications are features of a chronic inflammatory
Fig. 2 Representative histological sections of colon. (A) Normal non-transgenic F344 rats. (B, C) 18-week-old IgG2a,k-treated B27TR. (D) Early treatment with anti-TNF␣ mAb. (E) 27-weekold IgG2a,k-treated B27TR. (F) Late treatment with mAb anti-TNF␣. Haematoxylin-eosin staining. Original magnification ϫ20. (G) Histological score of colonic inflammation (range 0-12). (*P Ͻ 0.05 anti-TNF␣-treated B27TR versus IgG2a,k-treated B27TR).
Fig. 3 Detection of TNF␣ receptor 1 (TNF-R1) in colonic mucosal tissue. (A) Positive colonic intestinal epithelial cells (IEC) for TNF-R1 in non-transgenic F344 rats (arrow). (B) IgG2a,k-treated B27TR colon with weakly stained (arrow) or negative (arrowhead) IEC. (C) The early treatment with anti-TNF␣ mAb preserves the expression of TNF-R1 in IEC (arrows). (D) 27-week-old IgG2a,k-treated B27TR showed negative immunoreactivity for TNF-R1 in IEC. (E) The late treatment with anti-TNF␣ mAb restored the expression of TNF-R1 in IEC (arrows
Fig. 5 Immunohistochemistry for Fas and Fas-ligand (Fas-L) on colonic mucosal tissue. (A-C) Fas expression. (A) Fas-positive cells (arrow) in the lamina propria of non-transgenic F344 rats. (B) In IgG2a,k-treated B27TR, Fas-positive cells of the lamina propria significantly decreased, whereas positive intestinal epithelial cells (IEC) increased (arrowheads). (C) Anti-TNF␣ treatment increased significantly the number of Fas positive cells in the lamina propria (arrow), while the positive IEC decreased (arrowhead). (D, E) Fas-L expression. (D) In control non-transgenic F344 rats, Fas-L was expressed mainly by the IEC (arrowhead). (E) IgG2a,k-treated B27TR showed a higher number of positive cells in the lamina propria (arrows). (F) Anti-TNF␣ treatment had no effect on Fas-L expression in the lamina propria (arrow) compared to
In IEC, TNF-R1 seems to be involved in immune privilege, a mechanism that may limit the extent of lymphocyte infiltration tolerated within tissues, such as the colon [17, 19, 33, 34] [39] .
A role for TNF-R2 in this scenario cannot be clearly found and explained. TNF-R2 is not constitutively expressed and has no 
